BACKGROUND: Transcatheter arterial chemoembolization (TACE) is a widely used and well-established treatment for hepatocellular carcinoma (HCC). However, TACE loses its therapeutic efficacy when performed repeatedly, a phenomenon termed TACE refractoriness. c-Met is associated with malignant potential and with resistance to anti-tumor therapies in some kinds of cancers. AIMS: The aim of this study is to investigate the clinical impact of TACE on c-Met expression with the aim of understanding the mechanism underlying TACE refractoriness. METHODS: The effect of TACE on the c-Met expression level was investigated in vitro in HCC cell lines, and it was shown that c-Met expression is upregulated in HCC cell lines cultured under hypoxia and/or exposed to chemotherapeutic agents. The in vitro results were validated using 82 clinical samples of HCC with and without preoperative TACE treatment. RESULTS: c-Met upregulation was observed significantly more frequently in clinical samples of HCC that were treated with preoperative TACE than in samples with no TACE treatment. Increased c-Met expression was significantly associated with poor prognosis. Furthermore, the incidence of c-Met-positive expression was significantly higher in TACE-refractory HCC samples. CONCLUSIONS: TACE treatment upregulates c-Met expression in HCC and the upregulated c-Met expression may be responsible for TACE refractoriness.
BACKGROUND: Transcatheter arterial chemoembolization (TACE) is a widely used and well-established treatment for hepatocellular carcinoma (HCC). However, TACE loses its therapeutic efficacy when performed repeatedly, a phenomenon termed TACE refractoriness. c-Met is associated with malignant potential and with resistance to anti-tumor therapies in some kinds of cancers. AIMS: The aim of this study is to investigate the clinical impact of TACE on c-Met expression with the aim of understanding the mechanism underlying TACE refractoriness. METHODS: The effect of TACE on the c-Met expression level was investigated in vitro in HCC cell lines, and it was shown that c-Met expression is upregulated in HCC cell lines cultured under hypoxia and/or exposed to chemotherapeutic agents. The in vitro results were validated using 82 clinical samples of HCC with and without preoperative TACE treatment. RESULTS: c-Met upregulation was observed significantly more frequently in clinical samples of HCC that were treated with preoperative TACE than in samples with no TACE treatment. Increased c-Met expression was significantly associated with poor prognosis. Furthermore, the incidence of c-Met-positive expression was significantly higher in TACE-refractory HCC samples. CONCLUSIONS: TACE treatment upregulates c-Met expression in HCC and the upregulated c-Met expression may be responsible for TACE refractoriness.
Authors: Murugabaskar Balan; Eduardo Mier y Teran; Ana Maria Waaga-Gasser; Martin Gasser; Toni K Choueiri; Gordon Freeman; Soumitro Pal Journal: J Biol Chem Date: 2015-02-02 Impact factor: 5.157
Authors: Jason F Wiggins; Lynnsie Ruffino; Kevin Kelnar; Michael Omotola; Lubna Patrawala; David Brown; Andreas G Bader Journal: Cancer Res Date: 2010-06-22 Impact factor: 12.701
Authors: Andrew J Wagner; John M Goldberg; Steven G Dubois; Edwin Choy; Lee Rosen; Alberto Pappo; James Geller; Ian Judson; David Hogg; Neil Senzer; Ian J Davis; Feng Chai; Carol Waghorne; Brian Schwartz; George D Demetri Journal: Cancer Date: 2012-05-17 Impact factor: 6.860
Authors: H Eguchi; H Nagano; H Yamamoto; A Miyamoto; M Kondo; K Dono; S Nakamori; K Umeshita; M Sakon; M Monden Journal: Clin Cancer Res Date: 2000-07 Impact factor: 12.531
Authors: Song Liu; Guangji Yu; Qingdong Wang; Long Li; Ying Liu; Ke Du; Fei Zhang; Bangli Zhao; Guangsheng Zhao Journal: Am J Transl Res Date: 2021-12-15 Impact factor: 4.060